To include your compound in the COVID-19 Resource Center, submit it here.

DigiTx focuses on data in evolving landscape of digital health investing

DigiTx is focusing on data management and generation as it navigates digital therapeutics investing

As one of the few digital therapeutics-focused investors, DigiTx is parsing opportunities in the rapidly expanding field by homing in on companies that use or generate patient data in innovative ways.

DigiTx Partners was launched in 2016 as a partnership between Astellas Pharma Inc. (Tokyo:4503) and MPM Capital Inc. to invest in early-stage digital health companies.

The investment firm was Astellas’ answer to the question on every pharma’s mind at the time: how to learn more about digital therapeutics, according to Managing Director David Kim.

In the 2019 Back to School issue, BioCentury surveyed 25 pharma and big biotech companies, and found that nearly all have engaged in digital health deals. Some companies have gone all in with large-scale investments and the formation of JVs. For example, Sanofi (Euronext:SAN; NYSE:SNY) teamed up with Google Inc.’s Verily Health

Read the full 1367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers